<DOC>
	<DOCNO>NCT00811993</DOCNO>
	<brief_summary>This study evaluate safety tolerability R1507 combination 12 distinct standard chemotherapy drug regimens additional R1507 monotherapy arm patient advance malignant neoplasms.The 12 regimen test parallel . There 3 subset patient eligible study : untreated , treat require treatment , treat fail add R1507 represent suitable treatment disease . All regimen first test dos R1507 less maximally administer dose , tolerate , dose escalated subsequent patient . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study R1507 Combination With Multiple Standard Chemotherapy Treatments Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; malignant neoplasm ; fail prior standard curative therapy ; ECOG performance Status 0 1 ; adequate bone marrow , hepatic renal function ; life expectancy great 8 week . chemotherapy within 2 week start therapy ; prior irradiation within 4 week prior start therapy ; prior treatment agent target IGFIR inhibition , investigational agent ; major surgery significant traumatic injury within 2 week prior study start ; patient receive concurrent antibody immunotherapy ; exclusion criterion relate specific treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>